OCEANYX PHARMACEUTICALS, INC.

Biotech · Private

Largazole, a novel class I selective histone deacetylase (HDAC) inhibitor molecule derived from marine cyanobacterium, for treating colorectal and other solid tumors.

Grants
$291K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Process Chemistry of Largazole, a Marine HDAC Inhibitor with Anticancer Activity$291,335
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2767JSK THERAPEUTICS INC.—$963K
2768Wave Bye Inc.—$852K
2769DIAVACS, INC.—$850K
2770OCEANYX PHARMACEUTICALS, INC.——
2771Niche Biopharmaceuticals LLC—$525K
2772LACERTA THERAPEUTICS, INC.—$500K
2773StaphOff Biotech, Inc.—$25K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.